

Dagan O Lonsdale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7582627/publications.pdf>

Version: 2024-02-01

33
papers

6,171
citations

361296

20
h-index

414303

32
g-index

33
all docs

33
docs citations

33
times ranked

6860
citing authors

#	ARTICLE	IF	CITATIONS
1	International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA - Journal of the American Medical Association, 2009, 302, 2323.	3.8	2,682
2	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	2.9	843
3	Pharmacokinetic issues for antibiotics in the critically ill patient. Critical Care Medicine, 2009, 37, 840-851.	0.4	755
4	A Multicenter Randomized Trial of Continuous versus Intermittent β -Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1298-1305.	2.5	206
5	A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Critical Care, 2011, 15, R139.	2.5	174
6	A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts. PLoS Medicine, 2015, 12, e1001916.	3.9	163
7	First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents, 2010, 35, 156-163.	1.1	154
8	Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Annals of Intensive Care, 2012, 2, 35.	2.2	149
9	Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Critical Care, 2011, 15, R149.	2.5	141
10	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	1.3	129
11	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. Critical Care, 2015, 19, 28.	2.5	111
12	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2010, 65, 1771-1778.	1.3	102
13	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Critical Care, 2014, 18, 565.	2.5	87
14	Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Medicine, 2020, 46, 225-235.	3.9	86
15	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	54
16	Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 2600-2608.	1.3	48
17	Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2014, 43, 343-348.	1.1	45
18	The "top 100" drugs and classes in England: an updated "starter formulary" for trainee prescribers. British Journal of Clinical Pharmacology, 2018, 84, 2562-2571.	1.1	44

#	ARTICLE	IF	CITATIONS
19	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4577-4584.	1.4	38
20	Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3533-3537.	1.4	37
21	Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 321-333.	2.3	24
22	Diagnostic Challenges in Sepsis. <i>Current Infectious Disease Reports</i> , 2021, 23, 22.	1.3	19
23	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7402-7406.	1.4	14
24	Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 316-346.	1.1	14
25	β -Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3625-3634.	1.3	13
26	Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?. <i>Antibiotics</i> , 2020, 9, 51.	1.5	13
27	Understanding and managing medication in elderly people. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2013, 27, 767-788.	1.4	10
28	Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. <i>Chemotherapy</i> , 2019, 64, 173-176.	0.8	4
29	Global personalization of antibiotic therapy in critically ill patients. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 87-93.	0.4	4
30	Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials": <i>Clinical Pharmacokinetics</i> , 2018, 57, 1471-1472.	1.6	2
31	Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health" Approach. <i>Antibiotics</i> , 2019, 8, 237.	1.5	2
32	The clinical frailty scale " does it predict outcome of the very-old in UK ICUs?. <i>Journal of the Intensive Care Society</i> , 0, , 175114372110507.	1.1	2
33	A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples "To Treat or Not to Treat? That Is the Question. <i>Antibiotics</i> , 2022, 11, 452.	1.5	2